Basilea Pharmaceutica stock
BSLN.SWSIXBasilea Pharmaceutica AG, HealthcareISIN CH0011432447
74Score 74 out of 100, Strong
Price and trend
83 / 100
Price history
+53% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 24% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 59).
The price is 2.8% below its 52-week high. Largest decline in 20 years: 90% (March 2007 to November 2011).
Chart figures for advanced users
- SMA 50$81.89
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$69.21
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)59
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$55.33
- The lowest closing price of the last twelve months.
- Resistance$88.46
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Basilea Pharmaceutica AG belongs to the Biotechnology industry (Switzerland) and, with a market value of $1.07B, is number 183 of 289 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $278.95M (up 11.4% year on year) and earnings of $48.25M (down 48.2%).
- For fiscal 2026, analysts expect on average revenue of $337.91M (up 21.1%) and adjusted earnings per share of $6.88 (up 104.8%).
Show more
- MEQIRI Score 74 out of 100 (Strong): rank 82 of 702 in Healthcare, median 53.
- The P/E is 18.9 (Biotechnology median 21.7, own median of recent years 28.6).
- Our model puts fair value at $55.27, with the price 56% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High return on capitalReturn on invested capital 71.5% in fiscal 2025, Biotechnology median −24.3%.Profitability 94
- More cash than debtCash $211.22M, financial debt $100.16M.Stability 86
- High marginNet margin 21.2% over the last 12 months, Biotechnology median −103.7%.Profitability 94
Weaknesses
- Analysts expect falling earningsDown 22.6% a year through 2028 (estimates from 4 analysts).Growth 62
- DilutionShare count up 19% since 2020.Capital allocation 58
Its standout strengths are profitability and momentum.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Modestly overvaluedIn our model the price counts as cheap below $39.48 and expensive above $92.11 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $11.72 (cash-flow model) and $98.81 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 6.1%. At 7.1% the fair value would be $55.02, at 5.1% it would be $55.60.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 34.3% on the twelve months before. Revenue has grown strongly since 2006, at around 20% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 83%, operating 22%, net 17%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 16 Feb 2027in 95 days
- Last reported
- 18 Aug 2026EPS reported $2.53 (expected $3.97)below expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 25.2% since 15 Oct 2026.
- Earnings per share
- $6.88+25.2%
- Revenue
- $337.91M+6.7%
- Earnings per share
- $5.50+15.0%
- Revenue
- $359.75M+5.8%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +15.3%2026 revenue growth now expected at about 15% and operating profit growth raised to about 40% (before about 20%).
“Driven by the higher expected revenue, we are raising our operating profit guidance and now expect an increase by approximately 40% year-on-year compared with our previous expectation of around 20% increase.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 18 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at Basilea Pharmaceutica
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 74
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- SpyGlass PharmaSGP $1.11B47
- MoonLake ImmunotherapeuticsMLTX $1.1B35
- InventivaIVA.PA $1.09B31
- Seaport TherapeuticsSPTX $1.08B46
- VerastemVSTM $1.06B40
- Solid BiosciencesSLDB $1.06B39
- Vor BiopharmaVOR $1.05B47
- Jade BiosciencesJBIO $1.01B42
ETFs that hold Basilea Pharmaceutica
Held by 10 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Pharma Breakthrough UCITS ETFETLI | 2.82% | 0.49% | €26.29M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.07% | 0.30% | €3.45B |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.04% | 0.30% | €813.64M |
Show 5 more
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.03% | 0.39% | €1.49B |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.02% | 0.23% | €321.86M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 21 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.